SE0001916D0 - Novel formulation - Google Patents

Novel formulation

Info

Publication number
SE0001916D0
SE0001916D0 SE0001916A SE0001916A SE0001916D0 SE 0001916 D0 SE0001916 D0 SE 0001916D0 SE 0001916 A SE0001916 A SE 0001916A SE 0001916 A SE0001916 A SE 0001916A SE 0001916 D0 SE0001916 D0 SE 0001916D0
Authority
SE
Sweden
Prior art keywords
novel formulation
formulations
butylnitrone
disulfophenyl
tert
Prior art date
Application number
SE0001916A
Other languages
English (en)
Inventor
Mats J Andersson
Mattias Andersson
Patrik Eriksson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0001916A priority Critical patent/SE0001916D0/sv
Publication of SE0001916D0 publication Critical patent/SE0001916D0/sv
Priority to ARP010102188A priority patent/AR030218A1/es
Priority to TW090111180A priority patent/TWI259078B/zh
Priority to MYPI20012391A priority patent/MY130445A/en
Priority to PCT/SE2001/001164 priority patent/WO2001089507A1/en
Priority to NZ522329A priority patent/NZ522329A/en
Priority to CZ20023849A priority patent/CZ20023849A3/cs
Priority to AT01934785T priority patent/ATE303803T1/de
Priority to SK1654-2002A priority patent/SK16542002A3/sk
Priority to SI200130422T priority patent/SI1294369T1/sl
Priority to DE60113255T priority patent/DE60113255T2/de
Priority to HU0302310A priority patent/HUP0302310A3/hu
Priority to AU2001260935A priority patent/AU2001260935B2/en
Priority to ES01934785T priority patent/ES2247112T3/es
Priority to AU6093501A priority patent/AU6093501A/xx
Priority to EEP200200653A priority patent/EE200200653A/xx
Priority to CNB018098401A priority patent/CN1268326C/zh
Priority to MXPA02011533A priority patent/MXPA02011533A/es
Priority to KR1020027015761A priority patent/KR20030001545A/ko
Priority to JP2001585752A priority patent/JP3744857B2/ja
Priority to RU2002129588/15A priority patent/RU2271800C2/ru
Priority to PL36128401A priority patent/PL361284A1/xx
Priority to IL15253301A priority patent/IL152533A0/xx
Priority to EP01934785A priority patent/EP1294369B1/en
Priority to US10/276,747 priority patent/US20030181527A1/en
Priority to CA002408781A priority patent/CA2408781A1/en
Priority to DK01934785T priority patent/DK1294369T3/da
Priority to BR0111055-1A priority patent/BR0111055A/pt
Priority to ZA200208747A priority patent/ZA200208747B/en
Priority to IS6610A priority patent/IS6610A/is
Priority to NO20025461A priority patent/NO20025461L/no
Priority to HK03103875A priority patent/HK1051649A1/xx
Priority to US11/974,504 priority patent/US20080161406A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SE0001916A 2000-05-23 2000-05-23 Novel formulation SE0001916D0 (sv)

Priority Applications (33)

Application Number Priority Date Filing Date Title
SE0001916A SE0001916D0 (sv) 2000-05-23 2000-05-23 Novel formulation
ARP010102188A AR030218A1 (es) 2000-05-23 2001-05-09 Formulacion farmaceutica, proceso para su preparacion, y uso de la formulacion para la preparacion de perfusiones intravenosas.
TW090111180A TWI259078B (en) 2000-05-23 2001-05-10 Novel formulation
MYPI20012391A MY130445A (en) 2000-05-23 2001-05-21 Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
BR0111055-1A BR0111055A (pt) 2000-05-23 2001-05-22 Formulação farmacêutica, e, processo para a preparação e uso da mesma
AU6093501A AU6093501A (en) 2000-05-23 2001-05-22 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
JP2001585752A JP3744857B2 (ja) 2000-05-23 2001-05-22 アルファ−２，４−ジスルホフェニル−Ｎ−ｔｅｒｔ−ブチルニトロンの新規な処方物
CZ20023849A CZ20023849A3 (cs) 2000-05-23 2001-05-22 Nové farmaceutické prostředky na bázi alfa-(2,4-disulfofenyl)-N-terc. butylnitronu
AT01934785T ATE303803T1 (de) 2000-05-23 2001-05-22 Neue formulierungen von -g(a)-2,4-disulfophenyl-n-tert-butylnitron
SK1654-2002A SK16542002A3 (sk) 2000-05-23 2001-05-22 Nové prípravky alfa-(2,4-disulfofenyl)-N-terc-butylnitrónu
SI200130422T SI1294369T1 (sl) 2000-05-23 2001-05-22 Nove formulacije alfa-2,4-disulfofenil-N-terc.-butilnitrona
DE60113255T DE60113255T2 (de) 2000-05-23 2001-05-22 Neue formulierungen von -g(a)-2,4-disulfophenyl-n-tert-butylnitron
HU0302310A HUP0302310A3 (en) 2000-05-23 2001-05-22 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone and process for their preparation
AU2001260935A AU2001260935B2 (en) 2000-05-23 2001-05-22 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
ES01934785T ES2247112T3 (es) 2000-05-23 2001-05-22 Nuevas formulaciones de (a)-2,4-disulfofenil-n-terc-butilnitrona).
PCT/SE2001/001164 WO2001089507A1 (en) 2000-05-23 2001-05-22 NOVEL FORMULATIONS OF α-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE
EEP200200653A EE200200653A (et) 2000-05-23 2001-05-22 alfa-2,4-disulfofenüül-N-tert-butüülnitrooni uuedpreparaadid
CNB018098401A CN1268326C (zh) 2000-05-23 2001-05-22 α－2,4－二磺基苯基－N－叔丁基硝酮的新制剂
MXPA02011533A MXPA02011533A (es) 2000-05-23 2001-05-22 Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
KR1020027015761A KR20030001545A (ko) 2000-05-23 2001-05-22 α-2,4-디설포페닐-Ｎ-ｔｅｒｔ-부틸니트론의 신규 제제
NZ522329A NZ522329A (en) 2000-05-23 2001-05-22 Novel formulations of -2,4-disulfophenyl-N-tert-butylnitrone
RU2002129588/15A RU2271800C2 (ru) 2000-05-23 2001-05-22 Новые препараты альфа-2,4-дисульфофенил-n-трет-бутилнитрона
PL36128401A PL361284A1 (en) 2000-05-23 2001-05-22 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
IL15253301A IL152533A0 (en) 2000-05-23 2001-05-22 NOVEL FORMULATIONS OF alpha-2,4-DISULFOPHENYL-N-TERTBUTYLNITRONE
EP01934785A EP1294369B1 (en) 2000-05-23 2001-05-22 NOVEL FORMULATIONS OF $g(a)-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE
US10/276,747 US20030181527A1 (en) 2000-05-23 2001-05-22 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
CA002408781A CA2408781A1 (en) 2000-05-23 2001-05-22 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
DK01934785T DK1294369T3 (da) 2000-05-23 2001-05-22 Hidtil ukendte formuleringer med alfa-2,4-disulfophenyl-N-tert-bytylnitron
ZA200208747A ZA200208747B (en) 2000-05-23 2002-10-29 Novel formulations of alpha-2, 4-disulfophenyl-N-tert-butylnitrone.
IS6610A IS6610A (is) 2000-05-23 2002-11-11 Nýjar blöndur alfa-2,4-dísúlfófenýl-N-tert-bútýlnítróns
NO20025461A NO20025461L (no) 2000-05-23 2002-11-14 Nye formuleringer av <alfa>-(2,4-disulfofenyl)-N-tert- butylnitron
HK03103875A HK1051649A1 (en) 2000-05-23 2003-05-30 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
US11/974,504 US20080161406A1 (en) 2000-05-23 2007-10-12 Novel formulations of alpha-2,4-disulfophenyl-N-tert-butylnitrone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0001916A SE0001916D0 (sv) 2000-05-23 2000-05-23 Novel formulation

Publications (1)

Publication Number Publication Date
SE0001916D0 true SE0001916D0 (sv) 2000-05-23

Family

ID=20279797

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0001916A SE0001916D0 (sv) 2000-05-23 2000-05-23 Novel formulation

Country Status (30)

Country Link
US (2) US20030181527A1 (sv)
EP (1) EP1294369B1 (sv)
JP (1) JP3744857B2 (sv)
KR (1) KR20030001545A (sv)
CN (1) CN1268326C (sv)
AR (1) AR030218A1 (sv)
AT (1) ATE303803T1 (sv)
AU (2) AU2001260935B2 (sv)
BR (1) BR0111055A (sv)
CA (1) CA2408781A1 (sv)
CZ (1) CZ20023849A3 (sv)
DE (1) DE60113255T2 (sv)
DK (1) DK1294369T3 (sv)
EE (1) EE200200653A (sv)
ES (1) ES2247112T3 (sv)
HK (1) HK1051649A1 (sv)
HU (1) HUP0302310A3 (sv)
IL (1) IL152533A0 (sv)
IS (1) IS6610A (sv)
MX (1) MXPA02011533A (sv)
MY (1) MY130445A (sv)
NO (1) NO20025461L (sv)
NZ (1) NZ522329A (sv)
PL (1) PL361284A1 (sv)
RU (1) RU2271800C2 (sv)
SE (1) SE0001916D0 (sv)
SK (1) SK16542002A3 (sv)
TW (1) TWI259078B (sv)
WO (1) WO2001089507A1 (sv)
ZA (1) ZA200208747B (sv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
AU2010289838C1 (en) * 2009-08-24 2014-03-06 Hough Ear Institute Methods for treating acute acoustic trauma
EP2473527B1 (en) * 2009-09-03 2016-11-30 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US20120258926A1 (en) * 2009-12-15 2012-10-11 Valentyn Antochshuk Formulations of acadesine
JP6099574B2 (ja) 2011-02-04 2017-03-22 ハフ イヤ インスティテュート 外傷性脳損傷を処置する方法
CN104768532B (zh) * 2012-10-25 2017-11-28 费森尤斯卡比肿瘤学有限公司 5‑氮杂‑2’脱氧胞苷的稳定的药物组合物
US10660851B2 (en) 2015-01-02 2020-05-26 Rxos Medical Polyfunctional radical scavenger hydrogel formulation
CN116650411A (zh) * 2022-02-25 2023-08-29 广州喜鹊医药有限公司 一种注射用硝酮嗪药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2620413B2 (ja) * 1989-10-17 1997-06-11 オクラホマ メディカル リサーチ ファウンデーション 酸化的損傷に伴う疾患の阻止方法および組成物
JP2813023B2 (ja) * 1990-03-13 1998-10-22 株式会社神戸製鋼所 Ｍｉｓ型ダイヤモンド電界効果トランジスタ
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
US20080161406A1 (en) 2008-07-03
CZ20023849A3 (cs) 2003-05-14
DE60113255D1 (de) 2005-10-13
BR0111055A (pt) 2003-04-15
NO20025461D0 (no) 2002-11-14
TWI259078B (en) 2006-08-01
DE60113255T2 (de) 2006-06-08
HK1051649A1 (en) 2003-08-15
ZA200208747B (en) 2004-02-10
AR030218A1 (es) 2003-08-13
MY130445A (en) 2007-06-29
EE200200653A (et) 2004-06-15
RU2002129588A (ru) 2004-03-27
NO20025461L (no) 2002-11-14
ES2247112T3 (es) 2006-03-01
NZ522329A (en) 2004-07-30
EP1294369A1 (en) 2003-03-26
KR20030001545A (ko) 2003-01-06
EP1294369B1 (en) 2005-09-07
WO2001089507A1 (en) 2001-11-29
ATE303803T1 (de) 2005-09-15
CA2408781A1 (en) 2001-11-29
RU2271800C2 (ru) 2006-03-20
HUP0302310A3 (en) 2005-06-28
US20030181527A1 (en) 2003-09-25
CN1430510A (zh) 2003-07-16
MXPA02011533A (es) 2003-04-25
PL361284A1 (en) 2004-10-04
SK16542002A3 (sk) 2003-04-01
HUP0302310A2 (hu) 2003-11-28
DK1294369T3 (da) 2005-11-14
JP3744857B2 (ja) 2006-02-15
AU6093501A (en) 2001-12-03
JP2003534276A (ja) 2003-11-18
AU2001260935B2 (en) 2005-05-19
CN1268326C (zh) 2006-08-09
IS6610A (is) 2002-11-11
IL152533A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
HRP20020880B1 (en) New pharmaceutical composition
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
NO20022525L (no) Farmasöytiske formuleringer inneholdende zolmitriptan
DE60019334D1 (de) Antivirale arznei
SE9802208D0 (sv) Novel compounds
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
SE0001916D0 (sv) Novel formulation
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
NO323466B1 (no) Nye kinolinyl-piperidin-4-yliden-metyl-benzamidderivater, fremgangsmate til fremstilling derav, anvendelse derav i medikamenter til behandling av smerte, samt farmasoytisk sammensetning som innbefatter slike derivater
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
SE9802209D0 (sv) Novel compounds
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them
DE60003074D1 (de) Fusidinsäure-derivate
HUP0301337A2 (hu) Terbinafint tartalmazó orális gyógyszerkészítmények és alkalmazásuk
IT1320772B1 (it) Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale
DE60121142D1 (de) Zusammensetzung die paracetamol und niflumic säure enthält
SE9902674D0 (sv) New composition
ATE382363T1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
SE9902673D0 (sv) New composition
ITMI931822A1 (it) Composizioni farmaceutiche a base di nimesulide, somministrabili per via orale, non gastrolesive e/o a rilascio controllato